{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-005171","form_type":"8-K","ticker":"KYMR","cik":"0001815442","company_name":"Kymera Therapeutics, Inc.","filed_at":"2023-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.717841+00:00","generated_at":"2026-06-20T17:13:44.451091+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Kymera reports ~$560M cash, 2023 pipeline goals including KT-474 Phase 2 start with Sanofi","bullets":["Preliminary cash, cash equivalents and investments of ~$560M as of Dec 31, 2022, runway into H2 2025.","KT-474 (IRAK4 degrader) Phase 2 trials in HS and AD to initiate in 2023 in collaboration with Sanofi.","KT-333 (STAT3) Phase 1 dose escalation ongoing; 66% mean STAT3 degradation in PBMC at first dose level.","KT-413 (IRAKIMiD) Phase 1 completed two dose levels; dose-dependent degradation of IRAK4, Ikaros, Aiolos; no DLTs.","KT-253 (MDM2) IND cleared; Phase 1a to start Q1 2023 in solid tumors and hematological malignancies."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-005171","json":"https://secwatch.observer/filing/0001193125-23-005171.json","markdown":"https://secwatch.observer/filing/0001193125-23-005171.md","text":"https://secwatch.observer/filing/0001193125-23-005171.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815442/000119312523005171/0001193125-23-005171-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815442/000119312523005171/d447672d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T17:13:44.451091+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}